The University of Chicago Header Logo

Connection

Mark J. Ratain to Cost-Benefit Analysis

This is a "connection" page, showing publications Mark J. Ratain has written about Cost-Benefit Analysis.
Connection Strength

0.693
  1. Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy. Ann Oncol. 2023 08; 34(8):638-644.
    View in: PubMed
    Score: 0.190
  2. Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments. J Clin Oncol. 2021 03 20; 39(9):950-955.
    View in: PubMed
    Score: 0.163
  3. Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value. Clin Pharmacol Ther. 2020 09; 108(3):487-493.
    View in: PubMed
    Score: 0.154
  4. Value-based insurance design in oncology. Lancet Oncol. 2011 Apr; 12(4):321-3.
    View in: PubMed
    Score: 0.082
  5. Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies. Cancer J. 2009 Sep-Oct; 15(5):426-30.
    View in: PubMed
    Score: 0.074
  6. Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST). Cancer. 2017 02 01; 123(3):476-484.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.